Your browser doesn't support javascript.
loading
Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer.
Inoue, Hiroto; Ono, Akira; Kawabata, Takanori; Mamesaya, Nobuaki; Kawamura, Takahisa; Kobayashi, Haruki; Omori, Shota; Wakuda, Kazushige; Kenmotsu, Hirotsugu; Naito, Tateaki; Murakami, Haruyasu; Yasui, Kazuaki; Ogawa, Hirofumi; Onoe, Tsuyoshi; Endo, Masahiro; Harada, Hideyuki; Takahashi, Toshiaki.
Affiliation
  • Inoue H; Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Sunto-gun, Shizuoka, 411-8777, Japan.
  • Ono A; Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Sunto-gun, Shizuoka, 411-8777, Japan. a.ono@scchr.jp.
  • Kawabata T; Clinical Research Center, Shizuoka Cancer Center, Shizuoka, Japan.
  • Mamesaya N; Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Sunto-gun, Shizuoka, 411-8777, Japan.
  • Kawamura T; Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Sunto-gun, Shizuoka, 411-8777, Japan.
  • Kobayashi H; Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Sunto-gun, Shizuoka, 411-8777, Japan.
  • Omori S; Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Sunto-gun, Shizuoka, 411-8777, Japan.
  • Wakuda K; Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Sunto-gun, Shizuoka, 411-8777, Japan.
  • Kenmotsu H; Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Sunto-gun, Shizuoka, 411-8777, Japan.
  • Naito T; Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Sunto-gun, Shizuoka, 411-8777, Japan.
  • Murakami H; Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Sunto-gun, Shizuoka, 411-8777, Japan.
  • Yasui K; Division of Radiation Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
  • Ogawa H; Division of Radiation Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
  • Onoe T; Division of Radiation Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
  • Endo M; Division of Diagnostic Radiology, Shizuoka Cancer Center, Shizuoka, Japan.
  • Harada H; Division of Radiation Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
  • Takahashi T; Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Sunto-gun, Shizuoka, 411-8777, Japan.
Invest New Drugs ; 38(5): 1612-1617, 2020 10.
Article in En | MEDLINE | ID: mdl-32128667
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pneumonia / Carcinoma, Non-Small-Cell Lung / Chemoradiotherapy / Antineoplastic Agents, Immunological / Lung Neoplasms / Antibodies, Monoclonal Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Invest New Drugs Year: 2020 Document type: Article Affiliation country: Japan Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pneumonia / Carcinoma, Non-Small-Cell Lung / Chemoradiotherapy / Antineoplastic Agents, Immunological / Lung Neoplasms / Antibodies, Monoclonal Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Invest New Drugs Year: 2020 Document type: Article Affiliation country: Japan Country of publication: United States